Reducing treatment burden in cystic fibrosis (CF) is the top research priority for patients and clinicians. Difficulty accessing medication is one aspect of treatment burden. We investigated this with an online survey available globally for patients with CF and healthcare professionals. Almost three quarters of patients with CF in our survey report difficulty getting repeat prescriptions on time, and most community pharmacists experience interrupted supplies of CF-specific medications. These barriers affect emotional and physical health of people with CF. Two-thirds of people with CF would like to get all their CF medication from one place, their CF centre
Background: Psychological morbidity in individuals with cystic fibrosis (CF) and their caregivers is...
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic varian...
Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at bot...
Reducing treatment burden in cystic fibrosis (CF) is the top research priority for patients and clin...
In a recent James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF) the top priorit...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
BACKGROUND: Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in ...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
In a collaboration between health professionals and the patient community, we previously identified ...
Therapeutic intervention in cystic fibrosis (CF) remains a challenge, partly because of the number o...
Background Patients with cystic fibrosis (CF) are exposed to many drugs in their lifetime and many o...
Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is ...
Class of 2018 AbstractSpecific Aims: The aim of this systematic review and meta analysis is to deter...
This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) s...
Background: Psychological morbidity in individuals with cystic fibrosis (CF) and their caregivers is...
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic varian...
Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at bot...
Reducing treatment burden in cystic fibrosis (CF) is the top research priority for patients and clin...
In a recent James Lind Alliance Priority Setting Partnership in cystic fibrosis (CF) the top priorit...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
BACKGROUND: Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in ...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
There remain many treatment uncertainties in cystic fibrosis (CF). With limited resources, research ...
In a collaboration between health professionals and the patient community, we previously identified ...
Therapeutic intervention in cystic fibrosis (CF) remains a challenge, partly because of the number o...
Background Patients with cystic fibrosis (CF) are exposed to many drugs in their lifetime and many o...
Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is ...
Class of 2018 AbstractSpecific Aims: The aim of this systematic review and meta analysis is to deter...
This is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) s...
Background: Psychological morbidity in individuals with cystic fibrosis (CF) and their caregivers is...
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to the genetic varian...
Digital healthcare is a rapidly growing healthcare sector. Its importance has been recognised at bot...